New treatment strategies in Myasthenia gravis
Author:
- 7 October 2024
- journal article
- research article
- Published by Elsevier in Revue Neurologique
- Vol. 180 (9) , 971-981
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Myasthenic crisisMuscle & Nerve, 2023
- Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extensionJournal of Neurology, 2023
- Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia GravisJAMA Neurology, 2022
- Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia GravisJAMA Neurology, 2020
- Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell TransplantationJAMA Neurology, 2016
- Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysisJournal of Neurology, 2014
- Structural mechanisms of the agrin–LRP4–MuSK signaling pathway in neuromuscular junction differentiationCellular and Molecular Life Sciences, 2012
- Risk for myasthenia gravis maps to a 151Pro→Ala change in TNIP1 and to human leukocyte antigen‐B*08Annals of Neurology, 2012
- Advances in the understanding of the mechanism of action of IVIgJournal of Neurology, 2008
- Intravenous Immunoglobulin in Autoimmune Neuromuscular DiseasesJAMA, 2004